Phare Bio Joins Google.org Accelerator for AI-Driven Antibiotic Discovery
Phare Bio has been selected to participate in the Google.org Accelerator, a program aimed at advancing generative AI applications. Announced in a press release, Phare Bio will receive a share of $30 million in funding and six months of pro bono technical expertise to enhance its AI-powered, open-access drug discovery platform.
The platform, developed in collaboration with the Collins Lab at MIT, uses generative AI to design new classes of antibiotics. It integrates machine learning models with biological screening to identify and optimize drug candidates efficiently. This initiative addresses the growing issue of antibiotic resistance, which poses a significant global health threat.
Dr. Akhila Kosaraju, CEO and President of Phare Bio, emphasized the importance of this support in making their tools accessible to researchers worldwide, thereby accelerating antibiotic discoveries. The platform aims to develop 15 preclinical antibiotics by 2030, setting a new standard for biotech innovation.
Karla Palmer from Google.org highlighted Phare Bio's potential to revolutionize antibiotic discovery and foster global collaboration against urgent health challenges.
We hope you enjoyed this article
Consider subscribing to one of our newsletters like Life AI Weekly or Daily AI Brief.
Also, consider following us on social media:
More from Life Sciences
Oct 16 Study Tests Smartphone AI for Children's Lung Sounds Oct 16 Manhattan Physician Invests in RunPractice Oct 16 Attilio appoints Buck Institute CEO Eric Verdin as cochairman Oct 16 Aignostics launches HETA Clinical for pathology workflows Oct 16 Specialty1 Partners Invests in AI for Dental Practice OperationsLife AI Weekly
Weekly coverage of AI applications in healthcare, drug development, biotechnology research, and genomics breakthroughs.
Industry analysis
2025 Global Business Services Agenda: Gen AI Takes Center Stage
This industry analysis by The Hackett Group explores the transformative impact of generative artificial intelligence (Gen AI) on global business services (GBS) in 2025. The study highlights the shift from exploration to acceleration of Gen AI initiatives, with 89% of executives advancing these projects to improve customer satisfaction, innovate products, and reduce costs. The report also discusses the challenges and strategies for successful Gen AI adoption, emphasizing the need for a technology-enabled operating model and the importance of reskilling the workforce.
Read moreYou may also like
Zealand Pharma signs AI obesity drug deal worth up to $1.2 billion
Basecamp Research Raises $140 Million for AI Designed Therapeutics
Parakeet Health raises $10 million for AI patient access platform
Google Gives 200 European Scientists Access to AI Models
AbbVie Partners With Valkai on AI Tools for Clinical Development
Daily AI Brief: the AI news that matters, in your inbox.